StockTipsArenaBeta

BUY Cohance Lifesciences Limited — Rupak De, LKP Securities

BUYCohance Lifesciences Limited
Cohance Lifesciences share price target & all analyst calls

byRupak De, LKP SecuritiesHorizon: NA (inferred Swing (≤2wk))11 Aug 2026via CNBC Awaaz.

Entry₹468.6Inferred
Target₹500
Total upside +6.70% (call closed)
Stop loss₹457-2.48% risk
Exit₹45712 Aug 2026, 9:55 am
Stop-loss hit-2.48%
Follow Rupak De for new calls(16% target hit, 104 closed calls)Get alertsWatch COHANCE for new buy/sell callsGet alertsSee 114 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 12 Aug 2026
1 supporting3 neutral1 opposing
Supports the BUY call (1)

Cohance Lifesciences Stock Jumps Over 2% Despite Poor Q1 Earnings; Here's Why

NewsNdtv-Profit·6 Aug · 5d ago

(opens in new tab)
Neutral / worth noting (3)

Cohance Lifesciences’ Hyderabad plant gets USFDA observations: What it means for the pharma maker

NewsCnbc-Tv18·5 Aug · 6d ago

(opens in new tab)

Cohance Lifesciences Limited announced its unaudited financial results for Q1FY27, reporting revenue of ₹4,223 million (down 23.1% YoY) and adjusted EBITDA of ₹92 million. The company expects a reboun

NSE · Press Release·5 Aug · 6d ago

(opens in new tab)

Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · 6d ago

(opens in new tab)
Weighs against the BUY call (1)

Cohance Lifesciences Q1 Review: Brokerages Split After Earnings Slump — Check Potential Upside, Target Price

NewsNdtv-Profit·6 Aug · 6d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cohance Lifesciences

All analyst calls on Cohance Lifesciences

More from Rupak De, LKP Securities

Every call and its outcome